Supreme Court scrutiny exposes India's troubling medicine-pricing practices raising urgent questions about hospital mark-ups pharmaceutical profiteering and the affordability of cancer treatment.

There are few moments in life more devastating than hearing a doctor confirm that a loved one has cancer. For the patient it marks the beginning of a difficult medical journey, for the family it often signals the beginning of an exhausting financial struggle. Savings accumulated over decades begin to disappear, properties are sold, loans are taken and relatives are approached for financial assistance. Families that once enjoyed financial stability suddenly find themselves struggling to arrange money for the next chemotherapy session, injection or life-saving medicine. But an even more disturbing question arises when the price of a medicine bears little reasonable relationship to its procurement cost. How can an injection available through a distributor for approximately ₹11,000 end up costing a patient more than ₹1.30 lakh at a private hospital? Who benefits from this enormous difference and who is ultimately expected to bear the burden?
This is no longer simply a question being raised by distressed patients and their attendants. It has reached the Supreme Court of India where judicial scrutiny has brought the country's pharmaceutical pricing practices and hospital billing systems under an uncomfortable spotlight. The developments have exposed a fundamental weakness in India's healthcare ecosystem. The possibility that access to essential treatment can become a highly profitable commercial transaction at the expense of vulnerable patients.

The ₹1.30 Lakh Injection that Exposed a Disturbing Reality

One of the most striking incidents brought before the Supreme Court involved a medical distributor whose wife was undergoing cancer treatment at a prominent private hospital. According to the account presented in the proceedings the distributor informed the hospital that he could arrange the required chemotherapy injection at a dealer price of approximately ₹11,000. However the hospital reportedly declined to administer the medicine brought from outside and instead charged the family approximately ₹1.30 lakh for the injection.
Imagine the helplessness of a husband who understands the pharmaceutical business, knows the approximate procurement cost of the medicine and yet cannot persuade the hospital to administer it at a reasonable price while his wife is fighting cancer. The difference between ₹11,000 and ₹1.30 lakh is not an ordinary commercial margin. It raises serious questions about transparency, accountability and the extent to which hospitals should be permitted to impose their own pricing structures on essential medicines.
The matter became particularly significant during the 27th October 2026 proceedings when a Supreme Court bench comprising Justices Vikram Nath and Sandeep Mehta questioned the government over the pricing of medicines and the substantial differences between procurement costs and the amounts charged to patients. The Court also examined the practice of hospitals insisting that patients purchase medicines exclusively through their in-house pharmacies. Such arrangements can leave patients with little bargaining power. A family facing a medical emergency is hardly in a position to negotiate prices, compare suppliers or challenge a hospital's commercial policies. The issue therefore goes beyond one injection or one hospital. It concerns the larger question of whether healthcare institutions can exercise excessive commercial control over medicines that patients urgently require to survive.

Government Intervention Brings Substantial Price Reductions:

The Supreme Court's scrutiny has brought renewed urgency to a problem that patients and healthcare activists have been highlighting for years. Following earlier regulatory measures and sustained scrutiny of anti-cancer medicine prices the Centre moved towards rationalising trade margins on 137 identified non-scheduled anti-cancer medicines through the National Pharmaceutical Pricing Authority (NPPA). Under the Trade Margin Rationalisation mechanism an aggregate trade margin of 30% of the price to the retailer was prescribed for the identified medicines with the objective of curbing excessive mark-ups and improving affordability. The reported price revisions are remarkable.
The reduction in the price of Thiotepa is approximately 91% while Pertuzumab has become cheaper by approximately 68%. These figures demonstrate how regulatory intervention can make a substantial difference to the affordability of medicines. The revised prices are scheduled to take effect from 9TH November 2026.
For an ordinary family these reductions are not merely impressive percentages on a government announcement. A saving of more than ₹70,000 on a single medicine can determine whether a patient continues treatment without interruption or whether the family is forced to postpone essential medical care. The Centre has estimated that the 30% trade-margin cap covering the identified 137 anti-cancer medicines could generate annual savings of approximately ₹2,500 crore for patients. If implemented effectively this could represent an important step towards making cancer treatment more accessible.
However one question remains why did patients have to wait so long for such significant pricing interventions?
When cancer treatment becomes a financial catastrophe, behind every discussion about maximum retail prices, procurement costs, pharmaceutical margins and regulatory policies is a family fighting a battle that statistics can never fully describe. Consider a middle-class family whose primary earning member is diagnosed with cancer. Initially the family uses its savings. When those savings disappear it borrows money from relatives and friends. Jewellery is sold, land is mortgaged and loans are taken against whatever assets remain. Even after making these sacrifices there is no guarantee of recovery.
The situation becomes particularly painful when a doctor recommends a specific injection or medicine and the family discovers that its price is beyond its financial capacity. Imagine a father looking at his child knowing that a particular medicine may help prolong the child's life but being unable to arrange the required money. Imagine elderly parents watching their children struggle to finance another chemotherapy cycle. Cancer is already a devastating disease. Why should an opaque and excessively expensive medicine-pricing system make the suffering even more unbearable?
Healthcare cannot become a privilege reserved exclusively for those who can afford the most expensive hospitals and medicines. A patient's access to essential treatment should not depend entirely on the balance in their bank account. The tragedy is that families are often compelled to make decisions that no human being should have to make whether to sell their remaining property, borrow more money or discontinue treatment because the next dose is unaffordable. (To Be Continued)

Email:---------------------wanimudasirnazir@gmail.com